Arbutus to Participate in Upcoming Investor Conferences
February 09 2017 - 4:30PM
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that the company will be participating in upcoming
investor conferences.
- LEERINK Partners 6th Annual Global Healthcare Conference,
February 15-16, 2017, New York
- 2017 Disruptive Growth & Healthcare Conference, February
15, 2017, New York
- RBC Capital Markets 2017 Global Healthcare Conference, February
22-23, 2017, New York
Arbutus’ President and CEO, Dr. Mark J. Murray,
will participate in a fireside chat at the LEERINK conference on
February 16, 2017. A simultaneous webcast can be accessed by
visiting the Investor sections of www.arbutusbio.com and selecting
Events and Presentations. Replays will be available on the Arbutus
website following the event.
About Arbutus Arbutus Biopharma
Corporation is a biopharmaceutical company dedicated to
discovering, developing and commercializing a cure for patients
suffering from chronic HBV infection. Arbutus is headquartered in
Vancouver, BC, Canada with facilities in Doylestown, PA, USA. For
more information, visit www.arbutusbio.com.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: acutler@arbutusbio.com
Helia Baradarani
Senior Manager, Investor Relations
Phone: 604.419.3200
Email: hbaradarani@arbutusbio.com
Media
Please direct all media inquiries to: media@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024